Lonsurf® (FTD/TPI, Taiho Oncology) is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Read efficacy and safety information.

The latest issue of Oncology Issues features key insights from the inaugural ACCC Leadership Summit, strategies to adjust to rising patient volumes and workforce strain, advanced practice leadership models, and more.

In the third in a series of multidisciplinary consensus-building roundtables, ACCC and its partners explored ways to bridge the gap between community oncology programs and authorized treatment centers offering CAR T for patients with multiple myeloma.

In a recent conversation with ACCC, Kevan Simms, MBA, PMP, Assistant Vice President of Precision Medicine at Ochsner Health, shared how his organization is building a scalable stewardship model that not only improves current oncology care but also prepares for the future.

In a recent conversation with ACCC, DiMe Associate Program Director Ian Miller discussed what responsible AI adoption looks like in practice, particularly for organizations early in their AI journey and seeking clearer guidance on how to evaluate, prioritize, and implement these tools.
